Publication:
Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort

Simple item page
dc.contributor.authorTİNAY, İLKER
dc.contributor.authorsCetin T., Celik S., Sozen S., Ozen H., AKDOĞAN B., ASLAN G., BALTACI S., SÜER E., Bayazit Y., Izol V., et al.
dc.date.accessioned2024-10-14T16:51:28Z
dc.date.available2024-10-14T16:51:28Z
dc.date.issued2024-01-01
dc.description.abstractPurpose: To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications. Materials and Methods: Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype. Results: Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM. Conclusion: chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population.
dc.identifier.citationCetin T., Celik S., Sozen S., Ozen H., AKDOĞAN B., ASLAN G., BALTACI S., SÜER E., Bayazit Y., Izol V., et al., "Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort", Urology Journal, cilt.21, 2024
dc.identifier.doi10.22037/uj.v21i.8055
dc.identifier.issn1735-1308
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85205425967&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/298059
dc.identifier.volume21
dc.language.isoeng
dc.relation.ispartofUrology Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectNefroloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectNephrology
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (Med)
dc.subjectKlinik Tıp
dc.subjectÜroloji Ve Nefroloji
dc.subjectClinical Medicine (Med)
dc.subjectClinical Medicine
dc.subjectUrology & Nephrology
dc.subjectÜroloji
dc.subjectUrology
dc.subjectChromophobe RCC
dc.subjectClear cell RCC
dc.subjectKidney cancer
dc.subjectRecurrence
dc.subjectSurvival
dc.titleOncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort
dc.typearticle
dspace.entity.typePublication
local.avesis.idc5a2d515-917d-4163-a4c3-db29f777cd8e
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicationf54b9b38-576e-4b79-8b43-647b1e25292c
relation.isAuthorOfPublication.latestForDiscoveryf54b9b38-576e-4b79-8b43-647b1e25292c

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
354.87 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs